Integra LifeSciences Q2 revenue slightly beats, adjusted EPS tops estimates

Integra LifeSciences Holdings

29/07/2026 11:11

Overview
US medical technology firm's Q2 revenue rose 0.8%, a slight beat versus analyst expectations
Adjusted EPS for Q2 rose to $0.56, beating analyst expectations
Company reaffirmed full-year organic revenue growth and adjusted EPS guidance, lowered reported revenue outlook on FX

Outlook
Integra sees Q3 reported revenue between $410 mln and $425 mln
Company expects Q3 adjusted EPS of $0.53 to $0.61
Integra updates 2026 reported revenue guidance to $1.654 bln-$1.695 bln due to FX impact

Result Drivers
SPECIALTY SURGERY GROWTH - Revenue growth in Specialty Surgery was driven by higher sales in Neurosurgery (notably Certas Plus, Bactiseal and CUSA) and Instruments
TISSUE RECONSTRUCTION DECLINE - Tissue Reconstruction revenue fell due to a mid-single digit decline in wound reconstruction, with Integra Skin impacted by a tough prior-year comparison
SUPPLY RELIABILITY AND MANUFACTURING - Company cited improved supply reliability and initiation of production at its Braintree facility as supporting operational progress

Company press release: ID:nGNX3mrGHj

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Slight Beat*
$418.80 mln
$418.65 mln (10 Analysts)
Q2 Adjusted EPS
Beat
$0.56
$0.48 (10 Analysts)
Q2 EPS
 
$0.06
 
Q2 Adjusted Net Income
 
$43.70 mln
 
Q2 Adjusted EBITDA
 
$78.40 mln
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 6 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Integra Lifesciences Holdings Corp is $19.00, about 3.8% below its July 28 closing price of $19.76
The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 4 three months ago

Reuters Recommended Reads
July 27 - Boston Scientific unveils new restructuring plan, expects job cuts
July 28 - Philips falls 9% as weak orders, China concerns overshadow outlook hike
July 28 - IQVIA raises annual profit forecast on clinical research demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)